Who Paid My Doc
Skysona
Drug cerebral-adrenoleukodystrophy
NDC 73554-2111-1
General payments
$345,932
Research payments
$4,321,996
Through program year 2025, $345,932 in general payments and $4,321,996 in research payments were reported against Skysona (cerebral-adrenoleukodystrophy).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $1,242,036 | 59 |
| 2024 | General | $138,495 | 38 |
| 2024 | Research | $937,258 | 27 |
| 2023 | General | $207,437 | 57 |
| 2023 | Research | $2,142,703 | 19 |
Breakdown
The top 5 of 19 recipients; each share is of general payments naming this product in 2024.
The top 5 of 8 specialties; each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.
The top 5 of 10 states; each share is of general payments naming this product in 2024 where a state was reported.
Records
95 general · 105 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.